Actively Recruiting
Elranatamab in R/R Multiple Myeloma
Led by Massachusetts General Hospital · Updated on 2026-03-13
32
Participants Needed
3
Research Sites
247 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
P
Pfizer
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
CONDITIONS
Official Title
Elranatamab in R/R Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must provide signed informed consent before any study procedures.
- Participants must have an ECOG performance status of 0 or 1.
- Male or female participants aged 18 years or older.
- Women of child-bearing potential and men must agree to use adequate contraception before and during the study; men must continue for 4 months after treatment.
- Prior diagnosis of multiple myeloma according to IMWG criteria.
- Measurable multiple myeloma disease prior to idecabtagene vicleucel treatment, defined by specific protein levels in blood or urine.
- Previously treated relapsed and refractory multiple myeloma after idecabtagene vicleucel with at least a partial response.
- Left ventricular ejection fraction of 40% or higher.
- Adequate organ and marrow function, including specific counts for neutrophils, platelets, hemoglobin, creatinine clearance, and liver function.
- Ability to understand and willingness to sign informed consent.
You will not qualify if you...
- Patients with smoldering multiple myeloma, plasma cell leukemia, POEMS syndrome, or amyloidosis.
- Stem cell transplant within 12 weeks before enrollment or active graft-versus-host disease.
- Active hepatitis B or C, SARS-CoV2, HIV, or uncontrolled infections.
- Significant cardiovascular events or conditions within 6 months before enrollment.
- Any other active cancer within 3 years, except treated skin cancers or carcinoma in situ.
- Ongoing Grade 2 or higher peripheral neuropathy.
- History of Guillain-Barré syndrome or severe peripheral motor polyneuropathy.
- Previous treatment with an anti-BCMA bispecific antibody.
- Pregnant or breastfeeding women.
- Known hypersensitivity to elranatamab or its components.
- Receiving other investigational agents for this condition.
- Live vaccine within 4 weeks before study drug.
- Unresolved toxicity from prior cancer therapy except alopecia and peripheral neuropathy.
- Recent major surgery within 14 days before enrollment.
- Other medical or psychiatric conditions that increase risk or make participation unsuitable.
- Previous investigational drug use within 30 days or 5 half-lives before study drug administration.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
3
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
N
Noopur Raje, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here